Exosens Shares Drop Over 5% Testing a Key Technical Threshold at €61
Exosens drops more than 5% this Friday mid-session, trading at €61.00, while the CAC 40 is up by 0.79% at the same time. This downturn brings the stock close to its 50-day moving average and emphasizes a notable weekly decline of -6.44% over seven days.
Exosens stock is priced at €61.00, nearly touching its 50-day moving average (€61.15), a level that acts as a pivotal zone in the short term. A sustained breach below this threshold could pave the way towards the support identified at €57.50, close to the lower boundary of the Bollinger Bands (€56.33). The price is currently in the lower part of these bands, about 26% of the total amplitude, indicating significant selling pressure in recent sessions. The RSI, at 52, remains in a neutral zone and does not indicate overselling at this stage.
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
While the past week has weighed on the stock, the medium and long-term trajectory remains distinctly bullish. Over three months, Exosens has gained nearly 8%, and the increase reaches 101.3% over a year, marking a remarkable stock market journey since the company's debut. The price is significantly above the 200-day moving average (€48.61), a gap of more than 25% that reflects the strength of the underlying trend. The next key event for shareholders will be the release of the first quarter 2026 results, expected on April 27. This milestone could be a crucial catalyst for the stock's direction in the coming weeks. The general meeting is scheduled for May 22. Until then, the stock's low correlation with the market, indicated by a beta of 0.12, means that Exosens' movements are largely driven by company-specific factors rather than the general trend of the indices.
Nous sommes fiers de présenter notre performance sur les neuf premiers mois de l’année 2025, qui témoignent d'une croissance soutenue du chiffre d'affaires et de la marge brute ajustée, portée par la forte dynamique du secteur de la Défense.
Marché de la Défense très dynamique, forte demande pour la vision nocturne et les systèmes pour drones/anti-drones, croissance soutenue en Europe avec contribution des États-Unis et de l’Asie-Pacifique. Lancement commercial réussi des tubes 5G (plus de 5 000 commandes avant lancement).
Risks mentioned
Cession de l’activité Amplification par Micro-ondes entraînant une perte comptable sans impact de trésorerie en 2025
Dépendance aux budgets de Défense et aux évolutions géopolitiques
Risque d'intégration des acquisitions récentes
Incertitudes de la demande dans les Sciences de la Vie (marché américain)
Opportunities identified
Croissance adressable liée à la vision nocturne et aux applications drones/anti-drones
Commercialisation des tubes 5G avec commandes significatives (>5 000 tubes)
Expansion des capacités de production (+40% d’ici 2027) soutenant le développement commercial
Effets de croissance externe (Noxant, NVLS, Phasics) élargissant le marché adressable
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
